Share This Article:

Correlation between LDL-cholesterol and C-reactive protein among an apparently healthy population in the city of Athens

Abstract Full-Text HTML Download Download as PDF (Size:125KB) PP. 338-342
DOI: 10.4236/health.2011.36058    4,312 Downloads   8,423 Views   Citations

ABSTRACT

Background: The atherogenic LDL is an impor-tant generative cause for the endothelial dys-function and the configuration of the athero-sclerotic lesions. CRP is a sensitive marker of inflammation on the vascular wall, but also seems to participate in the atheromatic process. The correlation between LDL and CRP could form valuable guidelines for the initiation of a treatment with statins for individuals with an increased risk of ischemic incidents. Objectives: The aim of the study was to investigate a pos-sible correlation between LDL and CRP in an important number of apparently healthy indi-viduals. Methods: The study material consisted of the test results of 260 male and 484 female adults with normal LDL levels who were clini-cally healthy. The correlation between the LDL and the CRP values of this group was investi-gated in this group and CRP was compared with the respective values of a group of 60 male and 204 female adults with elevated LDL levels. Re-sults: It was ascertained that there is not a sta-tistically important correlation between LDL and CRP values in all groups (men, women, total) of the population with normal LDL levels. Addi-tionally, the CRP mean values were not statisti-cally different between the individuals with normal and raised LDL. Conclusion: A number of causes are incriminated for the results. More studies are definitely needed for the confirma-tion of the results, particularly if the findings could lead to the formation of guidelines for the application of a treatment in people with normal LDL levels but increased CRP levels.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Milionis, A. and Milionis, C. (2011) Correlation between LDL-cholesterol and C-reactive protein among an apparently healthy population in the city of Athens. Health, 3, 338-342. doi: 10.4236/health.2011.36058.

References

[1] Everett, B.M., Glynn, R.J., MacFadyen, J.G. and Ridker, P.M. (2010) Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation, 121, 143-150. doi:10.1161/CIRCULATIONAHA.109.874834
[2] Fan, J. and Watanabe, T. (2003) Inflammatory reactions in the pathogenesis of atherosclerosis. Journal of Atherosclerosis and Thrombosis, 10, 63-71.
[3] Stoll, G. and Bendszus, M. (2006) Inflammation and atherosclerosis—novel insights into plaque formation and destabilization. Stroke, 37, 1923-1932. doi:10.1161/01.STR.0000226901.34927.10
[4] Mora, S. and Ridker, P.M. (2006) Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER)—can C-reactive protein be used to target statin therapy in primary prevention? The American Journal of Cardiology, 97, 33A-41A. doi:10.1016/j.amjcard.2005.11.014
[5] Hirschfield, G.M. and Pepys, M.B. (2003) C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM: Monthly Journal of the Association of the Physicians, 96, 793-807.
[6] Venugopal, S.K., Devaraj, S. and Jialal, I. (2005) Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Current Opinion in Nephrology and Hypertension, 14, 33-37. doi:10.1097/00041552-200501000-00006
[7] Black, S., Kushner, I. and Samols, D. (2004) C-reactive protein. The Journal of Biological Chemistry, 279, 48487-48490. doi:10.1074/jbc.R400025200
[8] Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O. 3rd, Criqui, M., Fadl, Y.Y., Fortmann, S.P., Hong, Y., Myers, G.L., Rifai, N., Smith, S.C. Jr, Taubert, K., Tracy, R.P. and Vinicor, F. (2003) Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107, 499-511. doi:10.1161/01.CIR.0000052939.590
[9] Devaraj, S., Singh, U. and Jialal, I. (2009) The evolving role of C-reactive protein in atherothrombosis. Clinical Chemistry, 55, 229-238. doi:10.1373/clinchem.2008.108886
[10] Jialal, I., Devaraj, S. and Venugopal, S.K. (2004) C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension, 44, 6-11. doi:10.1161/01.HYP.0000130484.20501.df
[11] Ridker, P.M. (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation, 107, 363-369. doi:10.1161/01.CIR.0000053730.47739.3C
[12] Grundy, S.M., Cleeman, J.L., Merz, C.N., Brewer, H.B. Jr, Clark, L.T., Hunninghake, D.B., Pasternak, R.C., Smith, S.C. Jr and Stone, N.J. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 110, 227-239. doi:10.1161/01.CIR.0000133317.49796.0E
[13] Genest, J., McPherson, R., Frohlich, J., Anderson, T., Campbell, N., Carpentier, A., Couture, P., Dufour, R., Fodor, G., Francis, G.A., Grover, S., Gupta, M., Hegele, R.A., Lau, D.C., Leiter, L., Lewis, G.F., Lonn, E., Mancini, G.B., Ng, D., Pearson, G.J., Sniderman, A., Stone, J.A. and Ur, E. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. The Canadian Journal of Cardi
[14] Heart Protection Study Collaborative Group. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet, 360, 7-22. doi:10.1016/S0140-6736(02)09327-3
[15] The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The New England Journal of Medicine, 339, 1349-1357. doi:10.1056/NEJM199811053391902
[16] Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C., Davis, B.R. and Braunwald, E. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. The New England Journal of Medicine, 335, 1001-1009. doi:10.1056/NEJM199610033351401
[17] The Scandinavian Simvastatin Survival Study Group. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344,1383-1389.
[18] Abramson, J. and Wright, J.M. (2007) Are lipid-lowering guidelines evidence-based? Lancet, 369, 168-169. doi:10.1016/S0140-6736(07)60084-1
[19] Ravnskov, U., Rosch, P.J., Sutter, M.C. and Houston, M.C. (2006) Should we lower cholesterol as much as possible? BMJ (Clinical Research ed.), 332, 1330-1332. doi:10.1136/bmj.332.7553.1330
[20] Ridker, P.M. and the JUPITER Study Group. (2003) Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation, 108, 2292-2297. doi:10.1161/01.CIR.0000100688.17280.E6
[21] Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M. Jr, Kastelein, J.J., Koenig, W., Libby, P., Lorenzatti, A.J., MacFadyen, J.G., Nordestgaard, B.G., Shepherd, J., Willerson, J.T., Glynn, R.J. and the JUPITER Study Group (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine, 359, 2195-2207. doi:10.1056/NEJMoa0807646
[22] Albert, M.A., Danielson, E., Rifai, N., Ridker, P.M. and the PRINCE investigators (2001) Effect on statin therapy on C-reactive protein levels—the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA: The Journal of the American Medical Association, 286, 64-70. doi:10.1001/jama.286.1.64
[23] Ridker, P.M., Rifai, N. and Lowenthal, S.P. (2001) Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation, 103, 1191-1193.
[24] Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F. and Braunwald, E. (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators Circulation, 100, 230-235.
[25] Ferri, C., Croce, G., Cofini, V., De Berardinis, G., Grassi, D., Casale, R., Properzi, G. and Desideri, G. (2007) C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. Current Pharmaceutical Design, 13, 1631-1645. doi:10.2174/138161207780831301
[26] Tsimikas, S. and Miller, Y.I. (2011) Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Current Pharmaceutical Design, 17, 27-37. doi:10.2174/138161211795049831
[27] Lioudaki, E., Ganotakis, E.S. and Mikhailidis, D.P. (2011) Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Current Vascular Pharmacology, 9, 62-86. doi:10.2174/157016111793744760

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.